Результаты поиска

Руководящие принципы и консенсус в отношении минимально адаптированной к остаточным болезням терапии в множестве миеломы, выработанные Рабочей группой по миеломе в Пантихоокеанском регионе.

Лечение множественной миеломы (ММ) вступило в эру терапии, ориентированной на глубокую ремиссию, где минимальные остаточные заболевания (МВД) стали ключевым показателем реакции на лечение и долгосрочного прогнозирования, превосходя обычные критерии полной ремиссии. Однако оптимальная интеграция МРТ в процесс принятия клинических решений еще не достигнута. Этот экспертный консенсус предлагает основанные на фактических данных руководящие указания относительно пересмотра целей лечения в эпоху лечения на основе CD38, включения статуса MRD в терапевтические решения, стандартизации обнаружения MRD и

Measuring the Unseen Burden: Immunotherapy and Targeted Therapy Reduce Treatment-Related Time Toxicity in Incurable Malignancies.

BackgroundTreatment-related time toxicity (TrTT) poses a cumulative burden on quality of life. We aimed to analyze and quantify the impact of the TrTT on patients with incurable malignancies in our ambulatory oncology clinic.MethodsWe performed a retrospective observational analysis of the TrTT for individuals with incurable solid cancers at a regional safety-net oncology office that focuses on underserved communities. Time toxicity is calculated as the number of days a patient spent with any healthcare-related encounters during the initial 12-week period of the most recent line of therapy fro

Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials.

BACKGROUND: Multiple myeloma (MM) is the second most common hematologic malignancy worldwide. Recent therapeutic innovations, including the addition of daratumumab to standard regimens, have shown promising improvements in patient outcomes. OBJECTIVES: This study aims to compare the efficacy and safety of daratumumab-based quadruplet therapy regimens with standard triplet therapy regimens in newly diagnosed multiple myeloma (NDMM) patients. DESIGN: Systematic review and meta-analysis of randomized controlled trials. DATA SOURCES AND METHODS: A comprehensive literature search was conducted on P

Sacroplasty with or without screw fixation for sacral metastatic tumors.

INTRODUCTION: Cementation (sacroplasty) with or without ablation has been shown to improve pain and function for patients with sacral metastatic disease. Percutaneous screw fixation with sacroplasty (PSFS) may provide superior outcomes in select patients. METHODS: Thirty patients with sacral metastases who underwent sacroplasty with or without ablation and screw fixation at a single institution were retrospectively reviewed. Patients were compared based on treatment (PSFS or sacroplasty alone) and fracture status (pathological or impending) with an ANCOVA. Traumatic fractures were excluded. P

Cardiovascular adverse effects of immunotherapy in cancer: insights and implications.

Immunotherapy has revolutionized cancer treatment, offering novel therapeutic strategies such as immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines. However, these modalities are associated with varying cardiovascular toxicities that may affect treatment continuation and patient outcomes. Cardiovascular complications from ICIs, such as myocarditis (incidence 0.04-1.14%, mortality 25-50%), arrhythmias, heart failure, and thromboembolic events, are primarily mediated by autoreactive T-cell activation and immune-related inflammation. CTLA-4 an

Poster Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.

Advanced therapy medicinal products (ATMPs) require evaluation by the European Medicines Agency's Committee for Advanced Therapies prior to being placed on the European market, subject to a Marketing Authorisation granted by the European Commission. In common with other medicinal products, various regulatory pathways are available for taking ATMPs through clinical trials to market authorisation, and the regulatory pathway taken will depend on a product's characteristics and the target patient population. With the industry poised to deliver more late-stage clinical and commercial ATMPs for seri

Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models.

Background/Objectives: Magrolimab (Magro) is a humanized naked anti-CD47 monoclonal antibody that blocks the SIRPα CD47 interaction, allowing macrophages to target and destroy cancer cells. To evaluate its preclinical efficacy in vivo, Magro was tested as a single agent and in combination with conventional chemotherapy drugs, Cytarabine (Ara-C) or Azacitidine (Aza), in three pediatric AML (pAML) patient-derived xenograft (PDX) models-AML006 (KMT2A::MLLT1), AML010 (+10, WT1), and AML013 (KMT2A::MLLT4). Methods: After PDX model establishment, mice were assigned to treatment groups hulgG4 (VC, ve

The Role of a Navigational Radiofrequency Ablation Device and Concurrent Vertebral Augmentation for Treatment of Difficult-to-Reach Spinal Metastases.

AimsThe purpose of this study was to assess the effectiveness of a navigational radiofrequency ablation device with concurrent vertebral augmentation in the treatment of posterior vertebral body metastatic lesions, which are technically difficult to access. Primary outcomes of the study were evaluation of pain palliation and radiologic assessment of local tumor control.Materials and methodsThirty-five patients with 41 vertebral spinal metastases involving the posterior vertebral body underwent computed tomography-guided percutaneous targeted radiofrequency ablation, with a navigational radiofr

Virtual reality and hypnosis for symptom alleviation before bone marrow procedure.

Bone marrow aspiration biopsy (BMAB) commonly causes anxiety in patients, negatively affecting their overall procedural experience. We aimed to evaluate the efficacy of hypnosis and virtual reality (VR) compared to standard-of-care in improving concerns of patients undergoing BMAB. In this exploratory open-label randomized-controlled trial, adult patients undergoing BMAB were randomly assigned to hypnosis, VR, or control. Interventions included a 7-minute prerecorded hypnosis session or immersive VR experience immediately prior to the procedure. Patient concerns were measured using the Measure

Совпадение в полном тексте источника
… Although a ≥ 2-point MYCAW reduction has been proposed as a meaningful individual improvement in previous studies 19 , the minimal clinically important difference may vary across populations and settings, especially in invasive procedures such as BMAB. …

Daratumumab у поддающихся трансплантации пациентов с недавно диагностированным множественным миэломой: окончательный анализ клинических подгрупп в ГРИФФИН.

Случайный, фазы 2 Исследование ГРИФФИНNCT02874742) оценивалась " даратумумаб " плюс " линалидомид " / " бортезомиб "/дексаметасон " (D-RVD) в недавно диагностированной миеломе (NDMM). Мы представляем окончательный послекризисный анализ (средняя последующая деятельность, 49.6 - месяцев) подгрупп, имеющих отношение к клиническим заболеваниям, включая пациентов с повышенным риском цитогенетических аномалий (СПЧ) в соответствии с пересмотренным определением (del[17p], t[4;14], t[14;16], t[14;20], и/или прирост/и/или[1q21]). Полученные пациенты 4 индукционные цикл

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review.

INTRODUCTION: With an increase in number of cases of relapsed or refractory multiple myeloma (RRMM), scientist have discovered various combination of medications among which one is daratumumab, Daratumumab is a mono-clonal antibody which attacks CD-38 markers present in abundance on the surface of myeloma cells and is used universally for the treatment of primary newly diagnosed multiple myeloma patients. METHODS AND METHODOLOGY: This meta-analysis was conducted according to Cochrane Collaboration guidelines in which initially 679 articles were evaluated for relevance on abstract level follow

Практическое руководство по клиническому лечению окулярных неблагоприятных явлений, связанных с белантамбовым мафодотином у пациентов с повторной/редактированной множественной миеломой: рекомендации группы экспертов Японии.

Существенной причиной смертности является множественная миелома, а лечение пациентов с множественными миеломами с рецидивом/перестройкой имеет ограниченную эффективность. Режимы лечения с использованием белантамаба мафодотина свидетельствуют о значительном улучшении положения в плане обеспечения бесперебойного выживания по сравнению с нынешними стандартными режимами ухода, однако они связаны с повышенным риском возникновения окулярных неблагоприятных явлений (ОАЭ). Цель этих практических руководящих принципов состоит в том, чтобы дать рекомендации для оказания помощи японским врачам в управлен

Human Versus Machine in Survival Prediction for Metastatic Spinal Cord Compression: A Retrospective Cohort Study.

BackgroundAccurate survival prediction in metastatic spinal cord compression (MSCC) is critical for guiding treatment decisions, yet remains challenging, particularly for intermediate survival durations. We compared the accuracy of oncologist judgment, surgeon-calculated Tokuhashi scores, and ChatGPT-assisted predictions in estimating survival outcomes in MSCC patients.MethodsThis retrospective study included 100 patients (n = 100) referred to the Centre for Spinal Studies and Surgery, Queen's Medical Centre, a tertiary spinal oncology center in Nottingham, United Kingdom, with radiologically

Current Advancements in the Diagnosis and Treatment of Metastatic Spinal Cord Compression and Its Postintervention Care: A Comprehensive Review.

Malignant spinal cord compression (MSCC) is a serious oncological emergency that can result in neurological impairment and significant pain. It is associated with high morbidity, mortality, and a decrease in quality of life. This review reviews the current literature concerning diagnosis, guidelines, timely intervention, and management options in oncology patients with MSCC. A literature search of PubMed using relevant keywords and MeSH terms yielded 604 articles. Of these, 31 studies met the predefined inclusion criteria and were selected for detailed data extraction and synthesis into a narr

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors carfilzomib and ixazomib, the immunomodulatory agent pomalidomide, the monoclonal antibodies daratumumab and elotuzumab and the

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.

In relapsed and refractory multiple myeloma (RRMM), there are few treatment options once patients progress from the established standard of care. Several bispecific T-cell engagers (TCE) are in clinical development for multiple myeloma (MM), designed to promote T-cell activation and tumor killing by binding a T-cell receptor and a myeloma target. In this study we employ both computational and experimental tools to investigate how a novel trispecific TCE improves activation, proliferation, and cytolytic activity of T-cells against MM cells. In addition to binding CD3 on T-cells and CD38 on tumo

Сочетание результатов ММРГ GA и гематопоэтической оценки в целях оптимизации оценки динамической химиотерапии в множестве миелом.

Терпимость к химотерапии фона существенно влияет на эффективность лечения и выживаемость многих миэломы (ММ), особенно у слабых пациентов. Для оценки степени слабости широко используется Международная рабочая группа по гериатрической оценке миеломы (МРГГ), однако ограничения сохраняются. Динамические и комплексные подходы к оценке могут улучшить стратификацию рисков и способствовать индивидуализированному лечению. 111 Лечение вновь диагностированных пациентов ММ в третьей родственной больнице Университета Сан-Ят-сен (Ян) 2018-Jun 2024). МРГЗ ГА и Гематопоэтический счет (ГС) оценивались на осно

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.

BackgroundCost-effectiveness models require quality of life utilities calculated from generic preference-based questionnaires, such as EQ-5D. We evaluated the performance of available algorithms for QLQ-C30 conversion into EQ-5D-3L based utilities in a metastatic colorectal cancer (mCRC) patient population and subsequently developed a mCRC specific algorithm. Influence of mapping on cost-effectiveness was evaluated.MethodsThree available algorithms were compared with observed utilities from the CAIRO3 study. Six models were developed using 5-fold cross-validation: predicting EQ-5D-3L tariffs f

Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.

Novel therapeutic agents in clinical trials offer a paradigm shift in the approach to battling this prevalent and destructive disease, and the area of cancer therapy is on the precipice of a trans formative revolution. Despite the importance of tried-and-true cancer treatments like surgery, radiation, and chemotherapy, the disease continues to evolve and adapt, making new, more potent methods necessary. The field of cancer therapy is currently witnessing the emergence of a wide range of innovative approaches. Immunotherapy, including checkpoint inhibitors, CAR-T cell treatment, and cancer vacc